<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201419</url>
  </required_header>
  <id_info>
    <org_study_id>000233</org_study_id>
    <secondary_id>2016-003851-31</secondary_id>
    <nct_id>NCT03201419</nct_id>
  </id_info>
  <brief_title>A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults</brief_title>
  <acronym>DAWN</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate the efficacy, safety and tolerability of
      different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of
      treatment for nocturia due to nocturnal polyuria in adults
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 27, 2017</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Following randomisation, the first 125 subjects will be treated daily with placebo, FE 201836 or desmopressin for up to 12 weeks. Subjects may hereafter be randomised to one of 8 treatment groups for 12 weeks: placebo, 6 different doses of FE 201836, or desmopressin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Each subject will receive 2 medications (an oral solution and an orally disintegrating tablet (ODT) formulation) throughout the trial, in order to keep the treatment blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in number of nocturnal voids</measure>
    <time_frame>during 12 weeks of treatment</time_frame>
    <description>Nocturnal voids are defined as voids occuring from 5 minutes after bedtime until rising in the morning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in number of nocturnal voids</measure>
    <time_frame>Week 1, 4, 8 and 12</time_frame>
    <description>Nocturnal voids are defined as voids occuring from 5 minutes after bedtime until rising in the morning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate in nocturnal voids</measure>
    <time_frame>Week 1, 4, 8 and 12 and during 12 weeks of treatment</time_frame>
    <description>Defined as 50% reduction in nocturnal voids from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Nocturia Impact (NI) Diary Total Score</measure>
    <time_frame>Week 1, 4, 8 and 12 and during 12 weeks of treatment</time_frame>
    <description>Assessed by scores from 0-4 of 11 core items</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NI Diary Overall Impact Score</measure>
    <time_frame>Week 1, 4, 8 and 12 and during 12 weeks of treatment</time_frame>
    <description>Assessed by 1 overall Quality of Life (QoL) question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) urinary symptoms scores</measure>
    <time_frame>Week 1, 4, 8 and 12</time_frame>
    <description>Assessed by a patient questionnaire (summary of change in nocturia coded from 1-7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Patient Global Impression of Severity (PGI-S) scores</measure>
    <time_frame>Week 1, 4, 8 and 12</time_frame>
    <description>Assessed by a patient questionnaire (summary of severity of nocturia symptoms coded from 1-4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Bother</measure>
    <time_frame>Week 1, 4, 8 and 12</time_frame>
    <description>Assessed by the Hsu 5-point Likert Bother scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Insomnia Severity Index (ISI)</measure>
    <time_frame>Week 4, 8 and 12</time_frame>
    <description>Assessed by a patient questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in First Undisturbed Sleep Period (FUSP)</measure>
    <time_frame>Week 1, 4, 8 and 12 and during 12 weeks of treatment</time_frame>
    <description>FUSP is defined as the time in minutes from the time of going to bed to the time of first nocturnal void, or time of awakening if no void occured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in nocturnal diuresis rate (hourly) profiles</measure>
    <time_frame>Week 1 and 12</time_frame>
    <description>The nocturnal diuresis rate (mL/min) is calculated from the mean of 3 days Nocturnal Urine Volume (NUV) and total time in bed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in NUV</measure>
    <time_frame>Week 1 and 12</time_frame>
    <description>NUV is defined as the total urine volume from 5 minutes after bedtime with the intention to sleep until the first void within 30 minutes of rising in the morning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nights with at most one nocturnal void</measure>
    <time_frame>During 12 weeks of treatment</time_frame>
    <description>Calculated as percentage of nights during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nights with no nocturnal voids</measure>
    <time_frame>During 12 weeks of treatment</time_frame>
    <description>Calculated as percentage of nights during the treatment period</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Nocturia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Desmopressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Desmopressin ODT (25 μg for females and 50 μg for males)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 (1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 (2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 (3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 (4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 (5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 201836 (6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FE 201836</intervention_name>
    <description>Oral solution for daily intake</description>
    <arm_group_label>FE 201836 (1)</arm_group_label>
    <arm_group_label>FE 201836 (2)</arm_group_label>
    <arm_group_label>FE 201836 (3)</arm_group_label>
    <arm_group_label>FE 201836 (4)</arm_group_label>
    <arm_group_label>FE 201836 (5)</arm_group_label>
    <arm_group_label>FE 201836 (6)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmopressin</intervention_name>
    <description>Desmopressin Orally Disintegrating Tablet (ODT)</description>
    <arm_group_label>Desmopressin</arm_group_label>
    <other_name>NOCDURNA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral solution</intervention_name>
    <description>Manufactured to mimic experimental drug</description>
    <arm_group_label>Desmopressin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo ODT</intervention_name>
    <description>Manufactured to mimic active comparator drug</description>
    <arm_group_label>FE 201836 (1)</arm_group_label>
    <arm_group_label>FE 201836 (2)</arm_group_label>
    <arm_group_label>FE 201836 (3)</arm_group_label>
    <arm_group_label>FE 201836 (4)</arm_group_label>
    <arm_group_label>FE 201836 (5)</arm_group_label>
    <arm_group_label>FE 201836 (6)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 years of age (at the time of written consent)

          -  Medical history of, or subject reported nocturia symptoms during the 6 months prior to
             Visit 1

          -  ≥2 nocturnal voids (an average over 3 days) as documented in the 3-day e-Diary prior
             to Visit 2

          -  The largest single voided volume must be ≥200 mL (at least 1 void ≥200 mL) as
             documented in the 3-day e-Diary prior to Visit 2

          -  Nocturnal polyuria, defined as Nocturnal Polyuria index &gt;33%, a ratio of Nocturnal
             Urine Volume in excess of 33% of total daily (24-hour) urine volume as documented in
             the 3-day e-Diary prior to Visit 2

          -  ≥20% decrease in the nocturnal diuresis rate (mL/min) (that was recorded at Visit 2)
             as documented in the 3-day e-Diary prior to Visit 3

        Exclusion Criteria:

          -  Current diagnosis of Obstructive Sleep Apnoea (OSA)

          -  Restless Legs Syndrome (RLS)

          -  Bladder Outlet Obstruction (BOO) or urine flow &lt;5 mL/s, as confirmed by uroflowmetry
             upon suspicion during screening prior to Visit 2

          -  Urinary incontinence defined as an average of &gt;1 episode/day in the 3-day e-Diary
             prior to Visit 2 (occasional urge incontinence during daytime or at night on the way
             to void is not necessarily exclusionary)

          -  Any pelvic or lower urinary tract surgery and/or radio therapy or previous pelvic
             irradiation within the past 6 months prior to Visit 1. Including e.g., transurethral
             resection for Bladder Outlet Obstruction or Benign Prostatic Hyperplasia, hysterectomy
             or female incontinence procedures

          -  Genito-urinary tract pathology that can in the investigator's opinion be responsible
             for urgency or urinary incontinence e.g., symptomatic or recurrent urinary tract
             infections, interstitial cystitis, bladder-related pain, chronic pelvic pain syndrome,
             or stone in the bladder or urethra causing symptoms

          -  A history of cancer with the last date of disease activity/presence of malignancy
             within the last 12 months prior to Visit 1, except for adequately treated basal cell
             carcinoma of the skin

          -  History of any neurological disease affecting bladder function or muscle strength
             (e.g., Multiple Sclerosis, Parkinson's, spinal cord injury, spina bifida)

          -  Habitual (fluid intake &gt;3L per day) or psychogenic polydipsia

          -  Uncontrolled hypertension, as judged by the investigator

          -  Uncontrolled diabetes mellitus, as judged by the investigator

          -  Central or nephrogenic diabetes insipidus

          -  Known history of Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion

          -  History of gastric retention

          -  Suspicion or evidence of congestive heart failure, (New York Heart Association (NYHA)
             class II, III, IV)

          -  Hyponatraemia:

               -  Serum sodium level &lt;135 mmol/L at Visit 1(re-tested, with results available
                  within 7 days)

               -  Serum sodium level &lt;130 mmol/L at Visit 3 (re-tested, with results available
                  within 7 days)

          -  Use of any prohibited therapy listed below:

               -  Current or former (within 3 months prior to screening) treatment with any other
                  investigational medicinal product (IMP)

               -  Unstable electrostimulation or behavioural bladder training program less than 3
                  months prior to screening (stable electrostimulation or behavioural bladder
                  training program started at least 3 months before screening are acceptable)

               -  Thiazide diuretics

               -  Antiarrhythmic agents

               -  V2-receptor antagonists/agonists (e.g., vaptans/desmopressin, vasopressin)

               -  Loperamide

               -  Botulinum toxin (cosmetic non-urological use is acceptable)

               -  Valproate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Clinical Research, an AMR company</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri Valley Urology Medical Group</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Diego Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Rx Clinical Research Group, Inc.</name>
      <address>
        <city>Westminster</city>
        <state>California</state>
        <zip>92683</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Downtown Women's Health Care</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genitourinary Surgical Consultants, P.C.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Medical Research</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research Group, LLC</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Finlay Medical Research Corp</name>
      <address>
        <city>Green Acres</city>
        <state>Florida</state>
        <zip>33467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmax Research Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Research Institute Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanitas Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayside Clinical Research LLC</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pines Care Research Center, Inc</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Florida</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research, Inc.</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC</name>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <zip>46123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Network of Indiana, LLC</name>
      <address>
        <city>Greenfield</city>
        <state>Indiana</state>
        <zip>46140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay State Clinical Trials, Inc.</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beyer Research</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remedica LLC</name>
      <address>
        <city>Rochester</city>
        <state>Michigan</state>
        <zip>48307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Clinical Research Center, Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium, an AMR company</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119-5190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Hudson Medical Research, PLLC</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley, PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Health Research, Inc.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medication Management, LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peters Medical Research</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HWC Women's Research Center</name>
      <address>
        <city>Englewood</city>
        <state>Ohio</state>
        <zip>45322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NECCR Primacare Research, LLC</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center, Inc</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charleston, LLC</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MCA Research - Partner</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ericksen Research &amp; Development, LLC</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Research Institute</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater, an AMR company</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB Hopital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge - Campus Vercruysselaan</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultra-Med Inc.</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milestone Research</name>
      <address>
        <city>London</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKDS Research Inc.</name>
      <address>
        <city>Newmarket</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIEX Recherche Quebec Inc.</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Médicale St-Louis (Recherche) inc d/b/a/ Centre de Recherche Saint-Louis</name>
      <address>
        <city>Québec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bluewater Health-Norman Site</name>
      <address>
        <city>Sarnia</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS - Hôpital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIEX Recherche Sherbrooke Inc.</name>
      <address>
        <city>Sherbrooke</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Anil K. Gupta Medicine Professional Corporation</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DIEX Recherche Victoriaville Inc.</name>
      <address>
        <city>Victoriaville</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologie Benešov - Afimed s.r.o.</name>
      <address>
        <city>Benešov</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno, Dept of Klinika nemoci plicnich a tuberkulozy</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska nemocnice Liberec, a.s.</name>
      <address>
        <city>Liberec</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urocentrum Plzen</name>
      <address>
        <city>Plzen</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice, PARENT</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis fuer Urologie und Andrologie</name>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Emmendingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Weiden, Klinik f. Urologie, Andrologie und Kinderurologie</name>
      <address>
        <city>Weiden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc Del-pesti Korhaz es Rendelointezet</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Magyarorszag Kft.</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bagoly Egeszseghaz</name>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz Urologia</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Osrodek Badan Klinicznych</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyuria</mesh_term>
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

